{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:08:47Z","timestamp":1794600527282,"version":"4.9.1"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41571-024-00959-y","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T15:08:20Z","timestamp":1731683300000},"page":"10-27","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks"],"prefix":"10.1038","volume":"22","author":[{"given":"Caroline","family":"Diorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8030-7595","authenticated-orcid":false,"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"959_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"959_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/cancers15030663","volume":"15","author":"Y-J Chen","year":"2023","unstructured":"Chen, Y.-J., Abila, B. & Kamel, Y. M. CAR-T: what is next? Cancers 15, 663 (2023).","journal-title":"Cancers"},{"key":"959_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30062","volume":"70","author":"JC Molina","year":"2023","unstructured":"Molina, J. C. et al. Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: implications for adoptive cell therapy. Pediatr. Blood Cancer 70, e30062 (2023).","journal-title":"Pediatr. Blood Cancer"},{"key":"959_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","volume":"9","author":"RK Das","year":"2019","unstructured":"Das, R. K., Vernau, L., Grupp, S. A. & Barrett, D. M. Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 9, 492\u2013499 (2019).","journal-title":"Cancer Discov."},{"key":"959_CR5","doi-asserted-by":"publisher","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","volume":"8","author":"N Singh","year":"2016","unstructured":"Singh, N., Perazzelli, J., Grupp, S. A. & Barrett, D. M. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci. Transl. Med. 8, 320ra3 (2016).","journal-title":"Sci. Transl. Med."},{"key":"959_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"959_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou, A. J., Chen, L. C. & Chen, Y. Y. Navigating CAR-T cells through the solid-tumour microenvironment. Nat. Rev. Drug. Discov. 20, 531\u2013550 (2021).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"959_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1182\/blood.2019001859","volume":"135","author":"M Ruella","year":"2020","unstructured":"Ruella, M. et al. A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells. Blood 135, 505\u2013509 (2020).","journal-title":"Blood"},{"key":"959_CR9","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella, M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat. Med. 24, 1499\u20131503 (2018).","journal-title":"Nat. Med."},{"key":"959_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/1744666X.2020.1732819","volume":"16","author":"C Diorio","year":"2020","unstructured":"Diorio, C. & Teachey, D. T. Harnessing immunotherapy for pediatric T-cell malignancies. Expert. Rev. Clin. Immunol. 16, 361\u2013371 (2020).","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"959_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine, B. L., Miskin, J., Wonnacott, K. & Keir, C. Global manufacturing of CAR T cell therapy. Mol. Ther. Methods Clin. Dev. 4, 92\u2013101 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"959_CR12","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1001\/jamaoncol.2022.0319","volume":"8","author":"S Al Hadidi","year":"2022","unstructured":"Al Hadidi, S., Zangari, M. & van Rhee, F. Chimeric antigen receptor T-cell therapy in multiple myeloma-challenges and potential solutions. JAMA Oncol. 8, 823\u2013824 (2022).","journal-title":"JAMA Oncol."},{"key":"959_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jtct.2023.01.012","volume":"29","author":"T Kourelis","year":"2023","unstructured":"Kourelis, T. et al. Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience. Transpl. Cell Ther. 29, 255\u2013258 (2023).","journal-title":"Transpl. Cell Ther."},{"key":"959_CR14","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_397912","volume":"43","author":"ERS Cliff","year":"2023","unstructured":"Cliff, E. R. S. et al. High cost of chimeric antigen receptor T-cells: challenges and solutions. Am. Soc. Clin. Oncol. Educ. Book 43, e397912 (2023).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"959_CR15","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood.2019002258","volume":"134","author":"EA Chong","year":"2019","unstructured":"Chong, E. A. et al. CAR T cell viability release testing and clinical outcomes: is there a lower limit? Blood 134, 1873\u20131875 (2019).","journal-title":"Blood"},{"key":"959_CR16","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/1078-0432.CCR-22-2038","volume":"29","author":"I Aldoss","year":"2023","unstructured":"Aldoss, I. et al. Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed\/refractory ALL. Clin. cancer Res. 29, 742\u2013753 (2023).","journal-title":"Clin. cancer Res."},{"key":"959_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019).","journal-title":"Nature"},{"key":"959_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat. Rev. Drug. Discov. 19, 185\u2013199 (2020).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"959_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.37765\/ajmc.2021.88737","volume":"27","author":"R Borgert","year":"2021","unstructured":"Borgert, R. Improving outcomes and mitigating costs associated with CAR T-cell therapy. Am. J. Manag. Care 27, 253\u2013261 (2021).","journal-title":"Am. J. Manag. Care"},{"key":"959_CR20","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41409-020-0956-8","volume":"55","author":"S Fiorenza","year":"2020","unstructured":"Fiorenza, S., Ritchie, D. S., Ramsey, S. D., Turtle, C. J. & Roth, J. A. Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transpl. 55, 1706\u20131715 (2020).","journal-title":"Bone Marrow Transpl."},{"key":"959_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2072","volume":"3","author":"GH Lyman","year":"2020","unstructured":"Lyman, G. H., Nguyen, A., Snyder, S., Gitlin, M. & Chung, K. C. Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma. JAMA Netw. Open 3, e202072 (2020).","journal-title":"JAMA Netw. Open"},{"key":"959_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40259-017-0247-0","volume":"31","author":"M Ruella","year":"2017","unstructured":"Ruella, M. & Kenderian, S. S. Next-generation chimeric antigen receptor T-cell therapy: going off the shelf. BioDrugs 31, 473\u2013481 (2017).","journal-title":"BioDrugs"},{"key":"959_CR23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa, R. et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 389, 899\u2013910 (2023).","journal-title":"N. Engl. J. Med."},{"key":"959_CR24","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/mt.2015.104","volume":"23","author":"J Valton","year":"2015","unstructured":"Valton, J. et al. A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy. Mol. Ther. 23, 1507\u20131518 (2015).","journal-title":"Mol. Ther."},{"key":"959_CR25","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","volume":"6","author":"VA Fabrizio","year":"2022","unstructured":"Fabrizio, V. A. et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 6, 1961\u20131968 (2022).","journal-title":"Blood Adv."},{"key":"959_CR26","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","volume":"6","author":"L Dekker","year":"2022","unstructured":"Dekker, L. et al. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. Blood Adv. 6, 1969\u20131976 (2022).","journal-title":"Blood Adv."},{"key":"959_CR27","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood.2022016204","volume":"141","author":"W Qasim","year":"2023","unstructured":"Qasim, W. Genome-edited allogeneic donor \u201cuniversal\u201d chimeric antigen receptor T cells. Blood 141, 835\u2013845 (2023).","journal-title":"Blood"},{"key":"959_CR28","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood-2002-09-2687","volume":"102","author":"EC Morris","year":"2003","unstructured":"Morris, E. C. et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 102, 404\u2013406 (2003).","journal-title":"Blood"},{"key":"959_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/146532401317070899","volume":"3","author":"P Rebello","year":"2001","unstructured":"Rebello, P. et al. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 3, 261\u2013267 (2001).","journal-title":"Cytotherapy"},{"key":"959_CR30","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/TP.0b013e3181e7a3bf","volume":"90","author":"B Carpenter","year":"2010","unstructured":"Carpenter, B. et al. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation. Transplantation 90, 564\u2013570 (2010).","journal-title":"Transplantation"},{"key":"959_CR31","unstructured":"Beljanski, V. in xPharm: The Comprehensive Pharmacology Reference (eds Enna, S. J. & Bylund, D. B.) 1\u20134 (Elsevier, 2007)."},{"key":"959_CR32","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/2767-9764.CRC-22-0175","volume":"2","author":"S Dupouy","year":"2022","unstructured":"Dupouy, S. et al. Clinical pharmacology and determinants of response to UCART19, an allogeneic anti-CD19 CAR-T cell product, in adult B-cell acute lymphoblastic leukemia. Cancer Res. Commun. 2, 1520\u20131531 (2022).","journal-title":"Cancer Res. Commun."},{"issue":"Suppl. 1","key":"959_CR33","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1182\/blood-2022-169928","volume":"140","author":"DA Sallman","year":"2022","unstructured":"Sallman, D. A. et al. Ameli-01: a phase I trial of UCART123v1.2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R\/R) CD123+ acute myeloid leukemia (AML) [abstract]. Blood 140 (Suppl. 1), 2371\u20132373 (2022).","journal-title":"Blood"},{"key":"959_CR34","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","volume":"8","author":"Y Kagoya","year":"2020","unstructured":"Kagoya, Y. et al. Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy. Cancer Immunol. Res. 8, 926\u2013936 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"959_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44786-2","volume":"15","author":"J Ren","year":"2024","unstructured":"Ren, J. et al. Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-V\u03b22+ T cell malignancy. Nat. Commun. 15, 519 (2024).","journal-title":"Nat. Commun."},{"key":"959_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","volume":"39","author":"F Mo","year":"2021","unstructured":"Mo, F. et al. Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat. Biotechnol. 39, 56\u201363 (2021).","journal-title":"Nat. Biotechnol."},{"key":"959_CR37","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1182\/blood.2022016052","volume":"141","author":"F Mo","year":"2023","unstructured":"Mo, F. et al. Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood 141, 1194\u20131208 (2023).","journal-title":"Blood"},{"key":"959_CR38","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser, R. & Blazar, B. R. Acute graft-versus-host disease \u2013 biologic process, prevention, and therapy. N. Engl. J. Med. 377, 2167\u20132179 (2017).","journal-title":"N. Engl. J. Med."},{"key":"959_CR39","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser, R. & Blazar, B. R. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N. Engl. J. Med. 377, 2565\u20132579 (2017).","journal-title":"N. Engl. J. Med."},{"key":"959_CR40","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","volume":"119","author":"H Torikai","year":"2012","unstructured":"Torikai, H. et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119, 5697\u20135705 (2012).","journal-title":"Blood"},{"key":"959_CR41","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1002\/ajh.25399","volume":"94","author":"W Qasim","year":"2019","unstructured":"Qasim, W. Allogeneic CAR T cell therapies for leukemia. Am. J. Hematol. 94, S50\u2013S54 (2019).","journal-title":"Am. J. Hematol."},{"key":"959_CR42","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res. 23, 2255\u20132266 (2017).","journal-title":"Clin. Cancer Res."},{"key":"959_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30896-2","volume":"13","author":"S Jo","year":"2022","unstructured":"Jo, S. et al. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. Nat. Commun. 13, 3453 (2022).","journal-title":"Nat. Commun."},{"key":"959_CR44","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1182\/blood-2014-01-547737","volume":"123","author":"CH Geisler","year":"2014","unstructured":"Geisler, C. H. et al. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood 123, 3255\u20133262 (2014).","journal-title":"Blood"},{"key":"959_CR45","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/PPO.0000000000000511","volume":"27","author":"N Watanabe","year":"2021","unstructured":"Watanabe, N. & Mamonkin, M. Off-the-shelf chimeric antigen receptor T cells: how do we get there? Cancer J. 27, 176\u2013181 (2021).","journal-title":"Cancer J."},{"key":"959_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adn6509","volume":"9","author":"RP Patel","year":"2024","unstructured":"Patel, R. P. et al. CD5 deletion enhances the antitumor activity of adoptive T cell therapies. Sci. Immunol. 9, eadn6509 (2024).","journal-title":"Sci. Immunol."},{"key":"959_CR47","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1038\/s41375-023-02039-z","volume":"37","author":"J Xiang","year":"2023","unstructured":"Xiang, J. et al. An \u201coff-the-shelf\u201d CD2 universal CAR-T therapy for T-cell malignancies. Leukemia 37, 2448\u20132456 (2023).","journal-title":"Leukemia"},{"key":"959_CR48","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu, Y. et al. Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis. N. Engl. J. Med. 390, 1467\u20131480 (2024).","journal-title":"N. Engl. J. Med."},{"key":"959_CR49","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","volume":"25","author":"DT MacLeod","year":"2017","unstructured":"MacLeod, D. T. et al. Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells. Mol. Ther. 25, 949\u2013961 (2017).","journal-title":"Mol. Ther."},{"key":"959_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013","volume":"9","author":"W Qasim","year":"2017","unstructured":"Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med 9, eaaj2013 (2017).","journal-title":"Sci. Transl. Med"},{"key":"959_CR51","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","volume":"9","author":"R Benjamin","year":"2022","unstructured":"Benjamin, R. et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. 9, e833\u2013e843 (2022).","journal-title":"Lancet Haematol."},{"key":"959_CR52","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","volume":"396","author":"R Benjamin","year":"2020","unstructured":"Benjamin, R. et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 396, 1885\u20131894 (2020).","journal-title":"Lancet"},{"key":"959_CR53","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody, S. et al. Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat. Med. 29, 422\u2013429 (2023).","journal-title":"Nat. Med."},{"key":"959_CR54","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","volume":"24","author":"CE Brown","year":"2022","unstructured":"Brown, C. E. et al. Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma. Neuro Oncol. 24, 1318\u20131330 (2022).","journal-title":"Neuro Oncol."},{"key":"959_CR55","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 32, 995\u20131007 (2022).","journal-title":"Cell Res."},{"key":"959_CR56","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","volume":"31","author":"Y Fu","year":"2013","unstructured":"Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822\u2013826 (2013).","journal-title":"Nat. Biotechnol."},{"key":"959_CR57","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1182\/blood.2022015825","volume":"140","author":"C Diorio","year":"2022","unstructured":"Diorio, C. et al. Cytosine base editing enables quadruple-edited allogeneic CAR-T cells for T-ALL. Blood 140, 619\u2013629 (2022).","journal-title":"Blood"},{"key":"959_CR58","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00018-009-0188-y","volume":"67","author":"MJ Marcaida","year":"2010","unstructured":"Marcaida, M. J., Mu\u00f1oz, I. G., Blanco, F. J., Prieto, J. & Montoya, G. Homing endonucleases: from basics to therapeutic applications. Cell Mol. Life Sci. 67, 727\u2013748 (2010).","journal-title":"Cell Mol. Life Sci."},{"key":"959_CR59","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1016\/j.ymthe.2021.10.001","volume":"29","author":"T Murty","year":"2021","unstructured":"Murty, T. & Mackall, C. L. Gene editing to enhance the efficacy of cancer cell therapies. Mol. Ther. 29, 3153\u20133162 (2021).","journal-title":"Mol. Ther."},{"key":"959_CR60","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s11899-017-0417-7","volume":"12","author":"N Singh","year":"2017","unstructured":"Singh, N., Shi, J., June, C. H. & Ruella, M. Genome-editing technologies in adoptive T cell immunotherapy for cancer. Curr. Hematol. Malig. Rep. 12, 522\u2013529 (2017).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"959_CR61","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nm.2700","volume":"18","author":"E Provasi","year":"2012","unstructured":"Provasi, E. et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18, 807\u2013815 (2012).","journal-title":"Nat. Med."},{"key":"959_CR62","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nmeth.1670","volume":"8","author":"V Pattanayak","year":"2011","unstructured":"Pattanayak, V., Ramirez, C. L., Joung, J. K. & Liu, D. R. Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat. Methods 8, 765\u2013770 (2011).","journal-title":"Nat. Methods"},{"key":"959_CR63","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.omtn.2017.10.005","volume":"9","author":"AS Gautron","year":"2017","unstructured":"Gautron, A. S. et al. Fine and predictable tuning of TALEN gene editing targeting for improved T cell adoptive immunotherapy. Mol. Ther. Nucleic Acids 9, 312\u2013321 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"959_CR64","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","volume":"75","author":"L Poirot","year":"2015","unstructured":"Poirot, L. et al. Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies. Cancer Res. 75, 3853\u20133864 (2015).","journal-title":"Cancer Res."},{"key":"959_CR65","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1172\/JCI72992","volume":"124","author":"RM Gupta","year":"2014","unstructured":"Gupta, R. M. & Musunuru, K. Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J. Clin. Invest. 124, 4154\u20134161 (2014).","journal-title":"J. Clin. Invest."},{"key":"959_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04252-2","volume":"9","author":"M Adli","year":"2018","unstructured":"Adli, M. The CRISPR tool kit for genome editing and beyond. Nat. Commun. 9, 1911 (2018).","journal-title":"Nat. Commun."},{"key":"959_CR67","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq3010","volume":"14","author":"G Ottaviano","year":"2022","unstructured":"Ottaviano, G. et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci. Transl. Med. 14, eabq3010 (2022).","journal-title":"Sci. Transl. Med."},{"key":"959_CR68","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1182\/bloodadvances.2021006232","volume":"6","author":"Y Guo","year":"2022","unstructured":"Guo, Y. et al. CRISPR\/Cas9 genome-edited universal CAR T cells in patients with relapsed\/refractory lymphoma. Blood Adv. 6, 2695\u20132699 (2022).","journal-title":"Blood Adv."},{"key":"959_CR69","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1038\/s41375-023-02018-4","volume":"37","author":"S Li","year":"2023","unstructured":"Li, S. et al. CD7 targeted \u201coff-the-shelf\u201d CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies. Leukemia 37, 2176\u20132186 (2023).","journal-title":"Leukemia"},{"key":"959_CR70","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","volume":"19","author":"HA Rees","year":"2018","unstructured":"Rees, H. A. & Liu, D. R. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat. Rev. Genet. 19, 770\u2013788 (2018).","journal-title":"Nat. Rev. Genet."},{"key":"959_CR71","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.tibtech.2023.03.004","volume":"41","author":"Z Zhao","year":"2023","unstructured":"Zhao, Z., Shang, P., Mohanraju, P. & Geijsen, N. Prime editing: advances and therapeutic applications. Trends Biotechnol. 41, 1000\u20131012 (2023).","journal-title":"Trends Biotechnol."},{"key":"959_CR72","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.153323","volume":"7","author":"R Sagawa","year":"2022","unstructured":"Sagawa, R. et al. Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. JCI Insight 7, e153323 (2022).","journal-title":"JCI Insight"},{"key":"959_CR73","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32, 520\u2013531 (2018).","journal-title":"Leukemia"},{"key":"959_CR74","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial. Nat. Med. 30, 772\u2013784 (2024).","journal-title":"Nat. Med."},{"key":"959_CR75","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/0008-5472.CAN-22-2155","volume":"83","author":"P Schaible","year":"2023","unstructured":"Schaible, P., Bethge, W., Lengerke, C. & Haraszti, R. A. RNA therapeutics for improving CAR T-cell safety and efficacy. Cancer Res. 83, 354\u2013362 (2023).","journal-title":"Cancer Res."},{"key":"959_CR76","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1182\/bloodadvances.2017012823","volume":"2","author":"T Kamiya","year":"2018","unstructured":"Kamiya, T., Wong, D., Png, Y. T. & Campana, D. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells. Blood Adv. 2, 517\u2013528 (2018).","journal-title":"Blood Adv."},{"issue":"Suppl. 1","key":"959_CR77","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1182\/blood-2022-165822","volume":"140","author":"XFA Wong","year":"2022","unstructured":"Wong, X. F. A. et al. Development of an off-the-shelf chimeric antigen receptor (CAR)-T cell therapy for T-cell acute lymphoblastic leukemia (T-ALL) without gene editing [abstract]. Blood 140 (Suppl. 1), 2358\u20132359 (2022).","journal-title":"Blood"},{"key":"959_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03228-8","author":"BLZ Oh","year":"2024","unstructured":"Oh, B. L. Z. et al. Fratricide-resistant CD7-CAR T cells in T-ALL. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03228-8 (2024).","journal-title":"Nat. Med."},{"key":"959_CR79","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","volume":"14","author":"A Mitra","year":"2023","unstructured":"Mitra, A. et al. From bench to bedside: the history and progress of CAR T cell therapy. Front. Immunol. 14, 1188049 (2023).","journal-title":"Front. Immunol."},{"key":"959_CR80","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","volume":"27","author":"Y Hu","year":"2021","unstructured":"Hu, Y. et al. CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia. Clin. Cancer Res. 27, 2764\u20132772 (2021).","journal-title":"Clin. Cancer Res."},{"key":"959_CR81","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001511","volume":"8","author":"MV Maus","year":"2020","unstructured":"Maus, M. V. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J. Immunother. Cancer 8, e001511 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"959_CR82","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"959_CR83","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos, D. M. et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat. Med. 30, 2667\u20132678 (2024).","journal-title":"Nat. Med."},{"key":"959_CR84","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng, L., Sferruzza, G., Yang, L., Zhou, L. & Chen, S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol. Immunol. 21, 1089\u20131108 (2024).","journal-title":"Cell Mol. Immunol."},{"key":"959_CR85","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel, C. L. et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat. Rev. Clin. Oncol. 20, 49\u201362 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"959_CR86","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","volume":"14","author":"SK Pal","year":"2024","unstructured":"Pal, S. K. et al. CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma. Cancer Discov. 14, 1176\u20131189 (2024).","journal-title":"Cancer Discov."},{"key":"959_CR87","doi-asserted-by":"publisher","first-page":"100857","DOI":"10.1016\/j.crmeth.2024.100857","volume":"4","author":"AP Chen","year":"2024","unstructured":"Chen, A. P. et al. An improved approach to generate IL-15+\/+\/TGF\u03b2R2\u2212\/\u2212 iPSC-derived natural killer cells using TALEN. Cell Rep. Methods 4, 100857 (2024).","journal-title":"Cell Rep. Methods"},{"key":"959_CR88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142116","volume":"131","author":"H Shaim","year":"2021","unstructured":"Shaim, H. et al. Targeting the \u03b1v integrin\/TGF-\u03b2 axis improves natural killer cell function against glioblastoma stem cells. J. Clin. Invest. 131, e142116 (2021).","journal-title":"J. Clin. Invest."},{"key":"959_CR89","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.21.00389","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan, J. et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J. Clin. Oncol. 39, 3340\u20133351 (2021).","journal-title":"J. Clin. Oncol."},{"key":"959_CR90","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.clml.2020.04.007","volume":"20","author":"J Hua","year":"2020","unstructured":"Hua, J. et al. Allogeneic donor-derived anti-CD19 CAR T cell is a promising therapy for relapsed\/refractory B-ALL after allogeneic hematopoietic stem-cell transplantation. Clin. Lymphoma Myeloma Leuk. 20, 610\u2013616 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"959_CR91","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1172\/JCI138473","volume":"130","author":"CF Magnani","year":"2020","unstructured":"Magnani, C. F. et al. Sleeping beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. J. Clin. Invest. 130, 6021\u20136033 (2020).","journal-title":"J. Clin. Invest."},{"key":"959_CR92","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","volume":"16","author":"Y Tan","year":"2023","unstructured":"Tan, Y. et al. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. J. Hematol. Oncol. 16, 34 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"959_CR93","doi-asserted-by":"publisher","first-page":"334","DOI":"10.37349\/ei.2022.00054","volume":"2","author":"N Jhita","year":"2022","unstructured":"Jhita, N. & Raikar, S. S. Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies. Explor. Immunol. 2, 334\u2013350 (2022).","journal-title":"Explor. Immunol."},{"key":"959_CR94","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1182\/bloodadvances.2020002444","volume":"5","author":"MA de Witte","year":"2021","unstructured":"de Witte, M. A. et al. \u03b1\u03b2 T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies. Blood Adv. 5, 240\u2013249 (2021).","journal-title":"Blood Adv."},{"key":"959_CR95","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938\u2013945 (2015).","journal-title":"Nat. Med."},{"key":"959_CR96","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","volume":"20","author":"S Mensurado","year":"2023","unstructured":"Mensurado, S., Blanco-Dom\u00ednguez, R. & Silva-Santos, B. The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 178\u2013191 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"959_CR97","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.iotech.2019.06.002","volume":"1","author":"O Nussbaumer","year":"2019","unstructured":"Nussbaumer, O. & Koslowski, M. The emerging role of \u03b3\u03b4 T cells in cancer immunotherapy. Immunooncol. Technol. 1, 3\u201310 (2019).","journal-title":"Immunooncol. Technol."},{"key":"959_CR98","doi-asserted-by":"publisher","first-page":"863155","DOI":"10.3389\/fimmu.2022.863155","volume":"13","author":"GM Ferry","year":"2022","unstructured":"Ferry, G. M. et al. A simple and robust single-step method for CAR-V\u03b41 \u03b3\u03b4T cell expansion and transduction for cancer immunotherapy. Front. Immunol. 13, 863155 (2022).","journal-title":"Front. Immunol."},{"key":"959_CR99","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003441","volume":"9","author":"A Makkouk","year":"2021","unstructured":"Makkouk, A. et al. Off-the-shelf V\u03b41 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. J. Immunother. Cancer 9, e003441 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"959_CR100","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1373","volume":"11","author":"KP Nishimoto","year":"2022","unstructured":"Nishimoto, K. P. et al. Allogeneic CD20-targeted \u03b3\u03b4 T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models. Clin. Transl. Immunol. 11, e1373 (2022).","journal-title":"Clin. Transl. Immunol."},{"key":"959_CR101","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005400","volume":"10","author":"D Sanchez Martinez","year":"2022","unstructured":"Sanchez Martinez, D. et al. Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia. J. Immunother. Cancer 10, e005400 (2022).","journal-title":"J. Immunother. Cancer"},{"issue":"Suppl. 16","key":"959_CR102","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1200\/JCO.2022.40.16_suppl.7509","volume":"40","author":"SS Neelapu","year":"2022","unstructured":"Neelapu, S. S. et al. A phase 1 study of ADI-001: anti-CD20 CAR-engineered allogeneic gamma delta (\u03b3\u03b4) T cells in adults with B-cell malignancies [abstract]. J. Clin. Oncol. 40 (Suppl. 16), 7509 (2022).","journal-title":"J. Clin. Oncol."},{"key":"959_CR103","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nrclinonc.2014.215","volume":"12","author":"TC Lund","year":"2015","unstructured":"Lund, T. C., Boitano, A. E., Delaney, C. S., Shpall, E. J. & Wagner, J. E. Advances in umbilical cord blood manipulation \u2013 from niche to bedside. Nat. Rev. Clin. Oncol. 12, 163\u2013174 (2015).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"959_CR104","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1365-2141.2011.08598.x","volume":"154","author":"E Gluckman","year":"2011","unstructured":"Gluckman, E. et al. Milestones in umbilical cord blood transplantation. Br. J. Haematol. 154, 441\u2013447 (2011).","journal-title":"Br. J. Haematol."},{"key":"959_CR105","doi-asserted-by":"publisher","first-page":"35","DOI":"10.21037\/sci.2019.09.01","volume":"6","author":"Y Lin","year":"2019","unstructured":"Lin, Y. et al. Lower T cell inhibitory receptor level in mononuclear cells from cord blood compared with peripheral blood. Stem Cell Investig. 6, 35 (2019).","journal-title":"Stem Cell Investig."},{"key":"959_CR106","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jcyt.2016.05.001","volume":"18","author":"Q Ma","year":"2016","unstructured":"Ma, Q. et al. A novel TCR-like CAR with specificity for PR1\/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy 18, 985\u2013994 (2016).","journal-title":"Cytotherapy"},{"key":"959_CR107","doi-asserted-by":"publisher","first-page":"944248","DOI":"10.3389\/fonc.2022.944248","volume":"12","author":"DD Liu","year":"2022","unstructured":"Liu, D. D. et al. Umbilical cord blood: a promising source for allogeneic CAR-T cells. Front. Oncol. 12, 944248 (2022).","journal-title":"Front. Oncol."},{"key":"959_CR108","first-page":"8529104","volume":"2018","author":"S Berglund","year":"2018","unstructured":"Berglund, S., Gaballa, A., Sawaisorn, P., Sundberg, B. & Uhlin, M. Expansion of gammadelta T cells from cord blood: a therapeutical possibility. Stem Cell Int. 2018, 8529104 (2018).","journal-title":"Stem Cell Int."},{"key":"959_CR109","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3343\/alm.2022.42.6.638","volume":"42","author":"SK Koh","year":"2022","unstructured":"Koh, S. K. et al. Natural killer cell expansion and cytotoxicity differ depending on the culture medium used. Ann. Lab. Med. 42, 638\u2013649 (2022).","journal-title":"Ann. Lab. Med."},{"key":"959_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-76051-z","volume":"10","author":"T Calvo","year":"2020","unstructured":"Calvo, T. et al. Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance. Sci. Rep. 10, 19398 (2020).","journal-title":"Sci. Rep."},{"key":"959_CR111","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","volume":"24","author":"OK Dagher","year":"2023","unstructured":"Dagher, O. K. & Posey, A. D. Jr. Forks in the road for CAR T and CAR NK cell cancer therapies. Nat. Immunol. 24, 1994\u20132007 (2023).","journal-title":"Nat. Immunol."},{"key":"959_CR112","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/cancers15010117","volume":"15","author":"M W\u0142odarczyk","year":"2022","unstructured":"W\u0142odarczyk, M. & Pyrzynska, B. CAR-NK as a rapidly developed and efficient immunotherapeutic strategy against cancer. Cancers 15, 117 (2022).","journal-title":"Cancers"},{"key":"959_CR113","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood.2022016205","volume":"141","author":"F Cichocki","year":"2023","unstructured":"Cichocki, F., van der Stegen, S. J. C. & Miller, J. S. Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies. Blood 141, 846\u2013855 (2023).","journal-title":"Blood"},{"key":"959_CR114","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41375-019-0613-7","volume":"34","author":"C Quintarelli","year":"2020","unstructured":"Quintarelli, C. et al. Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia. Leukemia 34, 1102\u20131115 (2020).","journal-title":"Leukemia"},{"key":"959_CR115","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","volume":"15","author":"S Caruso","year":"2022","unstructured":"Caruso, S. et al. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. J. Hematol. Oncol. 15, 163 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"959_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59082-4","volume":"10","author":"N Mitwasi","year":"2020","unstructured":"Mitwasi, N. et al. \u201cUniCAR\u201d-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Sci. Rep. 10, 2141 (2020).","journal-title":"Sci. Rep."},{"key":"959_CR117","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"959_CR118","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.ccell.2024.07.007","volume":"42","author":"M Shanley","year":"2024","unstructured":"Shanley, M. et al. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer Cell 42, 1450\u20131466.e11 (2024).","journal-title":"Cancer Cell"},{"key":"959_CR119","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.2022016200","volume":"141","author":"MM Berrien-Elliott","year":"2023","unstructured":"Berrien-Elliott, M. M., Jacobs, M. T. & Fehniger, T. A. Allogeneic natural killer cell therapy. Blood 141, 856\u2013868 (2023).","journal-title":"Blood"},{"key":"959_CR120","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947\u2013953 (2020).","journal-title":"Nat. Biotechnol."},{"key":"959_CR121","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007705","volume":"11","author":"SM Abdin","year":"2023","unstructured":"Abdin, S. M. et al. Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia. J. Immunother. Cancer 11, e007705 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"959_CR122","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","volume":"25","author":"A Lei","year":"2024","unstructured":"Lei, A. et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat. Immunol. 25, 102\u2013116 (2024).","journal-title":"Nat. Immunol."},{"key":"959_CR123","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","volume":"31","author":"Z Shah","year":"2024","unstructured":"Shah, Z. et al. Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. Cell Stem Cell 31, 803\u2013817.e6 (2024).","journal-title":"Cell Stem Cell"},{"key":"959_CR124","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.3390\/cells11223692","volume":"11","author":"M Liu","year":"2022","unstructured":"Liu, M. et al. CAR-macrophages and CAR-T cells synergistically kill tumor cells in vitro. Cells 11, 3692 (2022).","journal-title":"Cells"},{"key":"959_CR125","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nri3369","volume":"13","author":"PJ Brennan","year":"2013","unstructured":"Brennan, P. J., Brigl, M. & Brenner, M. B. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat. Rev. Immunol. 13, 101\u2013117 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"959_CR126","doi-asserted-by":"publisher","first-page":"101241","DOI":"10.1016\/j.xcrm.2023.101241","volume":"4","author":"A Rotolo","year":"2023","unstructured":"Rotolo, A. et al. Unedited allogeneic iNKT cells show extended persistence in MHC-mismatched canine recipients. Cell Rep. Med. 4, 101241 (2023).","journal-title":"Cell Rep. Med."},{"key":"959_CR127","doi-asserted-by":"publisher","first-page":"5690","DOI":"10.1073\/pnas.95.10.5690","volume":"95","author":"T Kawano","year":"1998","unstructured":"Kawano, T. et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated V\u03b114 NKT cells. Proc. Natl Acad. Sci. USA 95, 5690\u20135693 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"959_CR128","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-immunol-032713-120243","volume":"32","author":"M Salio","year":"2014","unstructured":"Salio, M., Silk, J. D., Jones, E. Y. & Cerundolo, V. Biology of CD1- and MR1-restricted T cells. Annu. Rev. Immunol. 32, 323\u2013366 (2014).","journal-title":"Annu. Rev. Immunol."},{"key":"959_CR129","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","volume":"124","author":"A Heczey","year":"2014","unstructured":"Heczey, A. et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood 124, 2824\u20132833 (2014).","journal-title":"Blood"},{"key":"959_CR130","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","volume":"29","author":"A Heczey","year":"2023","unstructured":"Heczey, A. et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat. Med. 29, 1379\u20131388 (2023).","journal-title":"Nat. Med."},{"key":"959_CR131","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","volume":"34","author":"A Rotolo","year":"2018","unstructured":"Rotolo, A. et al. Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting. Cancer Cell 34, 596\u2013610.e11 (2018).","journal-title":"Cancer Cell"},{"issue":"Suppl. 1","key":"959_CR132","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1182\/blood-2021-149712","volume":"138","author":"CA Ramos","year":"2021","unstructured":"Ramos, C. A. et al. Allogeneic NKT cells expressing a CD19-specific CAR in patients with relapsed or refractory B-cell malignancies: an interim analysis [abstract]. Blood 138 (Suppl. 1), 2819 (2021).","journal-title":"Blood"},{"key":"959_CR133","doi-asserted-by":"publisher","first-page":"1118681","DOI":"10.3389\/fimmu.2023.1118681","volume":"14","author":"AG Rowan","year":"2023","unstructured":"Rowan, A. G. et al. CAR-iNKT cells targeting clonal TCRV\u03b2 chains as a precise strategy to treat T cell lymphoma. Front. Immunol. 14, 1118681 (2023).","journal-title":"Front. Immunol."},{"key":"959_CR134","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.3390\/ijms21113909","volume":"21","author":"A D\u00edaz-Basabe","year":"2020","unstructured":"D\u00edaz-Basabe, A., Strati, F. & Facciotti, F. License to kill: when iNKT cells are granted the use of lethal cytotoxicity. Int. J. Mol. Sci. 21, 3909 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"959_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20658-3","volume":"12","author":"S Iriguchi","year":"2021","unstructured":"Iriguchi, S. et al. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy. Nat. Commun. 12, 430 (2021).","journal-title":"Nat. Commun."},{"key":"959_CR136","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.stem.2018.12.011","volume":"24","author":"A Montel-Hagen","year":"2019","unstructured":"Montel-Hagen, A. et al. Organoid-induced differentiation of conventional T cells from human pluripotent stem cells. Cell Stem Cell 24, 376\u2013389.e8 (2019).","journal-title":"Cell Stem Cell"},{"key":"959_CR137","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.stem.2022.02.009","volume":"29","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. 3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells. Cell Stem Cell 29, 515\u2013527.e8 (2022).","journal-title":"Cell Stem Cell"},{"key":"959_CR138","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41551-022-00915-0","volume":"6","author":"SJC van der Stegen","year":"2022","unstructured":"van der Stegen, S. J. C. et al. Generation of T-cell-receptor-negative CD8\u03b1\u03b2-positive CAR T cells from T-cell-derived induced pluripotent stem cells. Nat. Biomed. Eng. 6, 1284\u20131297 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"959_CR139","first-page":"24","volume":"7","author":"T Ueda","year":"2023","unstructured":"Ueda, T. et al. Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. Nat. Biomed. Eng. 7, 24\u201337 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"959_CR140","doi-asserted-by":"publisher","first-page":"274","DOI":"10.5966\/sctm.2012-0084","volume":"2","author":"DA Knorr","year":"2013","unstructured":"Knorr, D. A. et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cell Transl. Med. 2, 274\u2013283 (2013).","journal-title":"Stem Cell Transl. Med."},{"key":"959_CR141","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00281-018-0721-x","volume":"41","author":"ML Saetersmoen","year":"2019","unstructured":"Saetersmoen, M. L., Hammer, Q., Valamehr, B., Kaufman, D. S. & Malmberg, K.-J. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells. Semin. Immunopathol. 41, 59\u201368 (2019).","journal-title":"Semin. Immunopathol."},{"key":"959_CR142","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","volume":"10","author":"X Xu","year":"2019","unstructured":"Xu, X. et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front. Immunol. 10, 2664 (2019).","journal-title":"Front. Immunol."},{"key":"959_CR143","doi-asserted-by":"publisher","first-page":"5982","DOI":"10.1182\/bloodadvances.2023009786","volume":"7","author":"SM Devine","year":"2023","unstructured":"Devine, S. M. et al. Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic. Blood Adv. 7, 5982\u20135993 (2023).","journal-title":"Blood Adv."},{"key":"959_CR144","doi-asserted-by":"publisher","first-page":"101136","DOI":"10.1016\/j.blre.2023.101136","volume":"63","author":"MS Odstrcil","year":"2023","unstructured":"Odstrcil, M. S., Lee, C. J., Sobieski, C., Weisdorf, D. & Couriel, D. Access to CAR T-cell therapy: focus on diversity, equity and inclusion. Blood Rev. 63, 101136 (2023).","journal-title":"Blood Rev."},{"key":"959_CR145","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113\u2013117 (2017).","journal-title":"Nature"},{"key":"959_CR146","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1016\/j.ymthe.2021.08.003","volume":"29","author":"B Akbari","year":"2021","unstructured":"Akbari, B. et al. Epigenetic strategies to boost CAR T cell therapy. Mol. Ther. 29, 2640\u20132659 (2021).","journal-title":"Mol. Ther."},{"issue":"Suppl. 3","key":"959_CR147","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000972520.32337.3f","volume":"7","author":"N Boissel","year":"2023","unstructured":"Boissel, N. et al. Updated results of the phase I balli-01 trial of Ucart22, an anti-Cd22 allogeneic car-T cell product, in patients with relapsed or refractory (R\/R) Cd22+ B-cell acute lymphoblastic leukemia (B-All) [abstract P1408]. Hemasphere 7 (Suppl. 3), e323373f (2023).","journal-title":"Hemasphere"},{"key":"959_CR148","unstructured":"Flaherty, C. FDA Grants Orphan Drug Designation to P-BCMA-ALLO1 in R\/R Multiple Myeloma. OncLive www.onclive.com\/view\/fda-grants-orphan-drug-designation-to-p-bcma-allo1-in-r-r-multiple-myeloma (2024)."},{"issue":"Suppl. 1","key":"959_CR149","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1182\/blood-2023-178723","volume":"142","author":"A Ghobadi","year":"2023","unstructured":"Ghobadi, A. et al. Phase 1\/2 dose-escalation\/dose-expansion study of anti-CD7 allogeneic CAR-T cells (WU-CART-007) in relapsed or refractory (R\/R) T-cell acute lymphoblastic leukemia\/ lymphoblastic lymphoma (T-ALL\/LBL) [abstract]. Blood 142 (Suppl. 1), 770 (2023).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"959_CR150","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1182\/blood-2023-186570","volume":"142","author":"JS Abramson","year":"2023","unstructured":"Abramson, J. S. et al. Preliminary results of Nathali-01: a first-in-human phase I\/IIa study of UCART20x22, a dual allogeneic CAR-T cell product targeting CD20 and CD22, in relapsed or refractory (R\/R) non-hodgkin lymphoma (NHL) [abstract]. Blood 142 (Suppl. 1), 2110 (2023).","journal-title":"Blood"},{"issue":"Suppl. 16","key":"959_CR151","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e19010","volume":"42","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. The interim analysis of a first-in-human phase 1 trial of ET-901, a CRISPR edited allogeneic immune-cloaked anti-CD19 CAR-T cell therapy in patients with r\/r B-NHL. J. Clin. Oncol. 42 (Suppl. 16), e19010 (2024).","journal-title":"J. Clin. Oncol."},{"key":"959_CR152","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jtct.2022.11.013","volume":"29","author":"Z Li","year":"2023","unstructured":"Li, Z. et al. Donor CD7 chimeric antigen receptor T cell bridging to allogeneic hematopoietic stem cell transplantation for T cell hematologic malignancy. Transplant. Cell. Ther. 29, 167\u2013173 (2023).","journal-title":"Transplant. Cell. Ther."},{"key":"959_CR153","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1002\/ajh.27094","volume":"98","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy. Am. J. Hematol. 98, 1898\u20131908 (2023).","journal-title":"Am. J. Hematol."},{"key":"959_CR154","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu, B. et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 20, 3025\u20133033 (2017).","journal-title":"Cell Rep."},{"key":"959_CR155","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1182\/blood-2022-162393","volume":"140","author":"J Svoboda","year":"2022","unstructured":"Svoboda, J. et al. Interleukin-18 secreting autologous anti-CD19 CAR T-cells (huCART19-IL18) in patients with non-Hodgkin lymphomas relapsed or refractory to prior CAR T-cell therapy. Blood 140, 4612\u20134614 (2022).","journal-title":"Blood"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00959-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00959-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00959-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T14:02:54Z","timestamp":1734530574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00959-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":155,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["959"],"URL":"https:\/\/doi.org\/10.1038\/s41571-024-00959-y","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"14 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.T.T. serves on advisory boards (unpaid) for Amgen, BEAM Therapeutics, Janssen, Jazz Pharmaceuticals, Servier and Sobi; receives research funding from BEAM Therapeutics; and has patents pending relating to cytokine-release syndrome after chimeric antigen receptor (CAR) T cell therapy and to CD38-directed CAR T cells. S.A.G. receives research funding from Cellectis, Kite (a GILEAD company), Novartis, Servier and Vertex; consults for Adaptive Biotech, Eureka Therapeutics, Estrella Immunopharma, Jazz Pharmaceuticals and Novartis; and has advised for Allogene, Cabaletta Bio, Jazz Pharmaceuticals, Novartis, Verismo and Vertex, and has patents related to CAR T toxicity managed by the\u00a0University of Pennsylvania. C.D. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}